From the Journals

Safe, effective backup for U.S. MMR vaccine exists


 

FROM HUMAN VACCINES & IMMUNOTHERAPEUTICS

Antibodies against measles, mumps, and rubella persisted for up to 2 years after vaccination of children 12-15 months with the MMR vaccine approved in the United States and a similar one approved in Europe, both of which are manufactured without human serum albumin, Andrea A. Berry, MD, at the University of Maryland, Baltimore, and her associates said.

In 752 children aged a mean 12 months who received either the United States MMR vaccine and the European one, seropositivity for measles, mumps, and rubella persisted for up to 2 years with both vaccines. Both vaccines also were well tolerated.

Vaccine syringe copyright luiscar/Thinkstock
The children also received single doses of hepatitis A vaccine, varicella vaccine, and the fourth dose of the 7-valent pneumococcal conjugate vaccine concomitantly.

Because there is only one MMR vaccine licensed in the United States, interruption to this single supply line could present a public health risk, Dr. Berry and her associates said. As both the vaccines used in this study do not contain human serum albumin, the theoretical risk of microbial contamination is reduced, compared with previous formulations of MMR.

Read more at Human Vaccines Immunotherapeutics. (2017. doi: 10.1080/21645515.2017.1309486).

Recommended Reading

Revaccinate HIV-infected teens with hepatitis B vaccine
MDedge Infectious Disease
Preterm infants face increased pertussis risk
MDedge Infectious Disease
WHO’s malaria pilot vaccine: No silver bullet, but a potential strike at malaria’s heart
MDedge Infectious Disease
International travel vaccination updates
MDedge Infectious Disease
Rotavirus vaccination in last decade cuts AGE hospitalization
MDedge Infectious Disease
U.S. yellow fever vaccine stocks could be depleted within months
MDedge Infectious Disease
Two doses HPV vaccine are as good as three against genital warts
MDedge Infectious Disease
Flu shots may spark immune adverse events in PD-1 blockade for NSCLC
MDedge Infectious Disease
Lower-dose aluminum hydroxide–adjuvanted polio vaccine noninferior to standard IPV
MDedge Infectious Disease
Adult vaccination is low, with minimal improvement in recent years
MDedge Infectious Disease